Find a TenderPast planning noticePreliminary market engagement notice
Published 21 Mar 2025, 08:17 GMT

Official UK procurement notice

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Official notice

Authority: NHS England (Central government)

Framework agreementGoodsAbove thresholdSME suitable
Sectors: Medical Devices & Pharma (33) Delivery: UK
Planned pipeline value£1,516,353,164pipeline notice, not a live tender
Tender notice expected 2 Jun 2025from the planned procurement notice
Framework period 1 yr 6 moends 31 May 2027 · up to 31 May 2029 with extensions · starts 1 Dec 2025

What is being bought

Published requirement description

Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of;

  • neovascular (wet) age-related macular degeneration (AMD)
  • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • proliferative diabetic retinopathy (PDR)
  • visual impairment due to diabetic macular oedema (DME)
  • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
  • vision impairment associated with chronic diabetic macular oedema, (DME)
  • visual impairment due to myopic choroidal neovascularisation (myopic CNV)
  • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease
  • inflammation of the posterior segment of the eye presenting as non-infectious uveitis
  • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

CPV: Pharmaceutical products · Various medicinal products

How this framework works

From the published notice
Framework period
1 yr 6 mo · up to 3 yrs 6 mo from 1 Dec 2025

The lotProcurement structure

single lot · no lot value published
Lot #1PlannedRenewal 1 yr 6 moSME
Contract period: 1 Dec 2025 – 31 May 2027 (1 yr 6 mo) · up to 31 May 2029 with extensions
Delivery: UKEligibility: SME eligible
Extensions: Extension options published

What it takes to win
i

How this buyer will score bids.

The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).

Evaluation split and conditions of participation as published; the tender pack may add more
What this means for your bid
  • “NHS National Framework for Medical Retinal Vascular Treatments - 1…” is a framework: the contest is a place on its panel, not a single contract.

Procedure terms & legal framework

From the official record
Legal basis
UKPGA · 2023/54 Procurement Act 2023
Procurement category
Goods
Notice status
Past planning notice
Procurement threshold
Above threshold (FTS publication)
Regulatory regime
Standard
Commercial structure
Framework agreement
Who may use this agreement
Not stated in the notice; call-off rights may be limited to the establishing authority
Competition type
Competitive procedure
GPA / WTO covered
Unspecified in notice
Recurring procurement
Unspecified in notice
First published
21 Mar 2025, 08:17 GMT
Last source update
21 Mar 2025, 08:17 GMT
Authority reference
C346388
FTS notice number
2025/S 000-010543
Latest notice
Preliminary market engagement notice (UK2)
Classification (CPV)
Pharmaceutical productsVarious medicinal products
Delivery area
UK
Official registry OCID
ocds-h6vhtk-04f707 Find a Tender

How it was run

Official notice
Appointment period ends
—

Timeline

21 Mar 2025 → 1 Dec 2025 · 4 dates
  1. Planning notice published
    21 Mar 2025, 08:17 GMT
  2. Market engagement
    11 Apr 2025, 23:59 BST

    NHS England is pleased to invite suppliers to a virtual 1:1 preliminary market engagement meeting in relation to the upcoming re-tender of the Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines Framework. The purpose of the sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, clinical aspects and KPI's. Please contact b.kullootee@nhs.net or michelle.clarke6@nhs.net to register your interest. There will also be a 7 day window for queries to be raised in writing after all sessions have concluded.

  3. Tender notice expected
    2 Jun 2025, 23:59 BST
  4. Contract starts332 days ago
    1 Dec 2025

Notice history

1 event · 1 release on Find a Tender
  1. Preliminary market engagement notice published
    21 Mar 2025, 08:17 GMT
    UK2

Commercial outcome & contract awards

Pipeline notice
Awards (0)
No award published
Contracts (0)
No contract published
Bid statistics
No aggregate bid statistics published

Contracting authority & participating public bodies

NHS England

Contracting authorityPublic authority - central government GB-PPON: PDPT-3135-BWWY Wellington House, 133-135 Waterloo Rd, London, London, SE1 8UGContact name, email

Official documents & specifications (1)

Official links; attachments are not copied

Notices published for this procedure